ClinicalTrials.gg
RecruitingNCT07846345Updated Sep 29, 2026

Case Management for Microtia

An interventional study of Microtia case-management platform in Congenital Microtia, sponsored by Jing Xu. Recruiting at 1 site in China. Open to participants aged 6 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Jing Xu · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
188
Allocation
Non-randomized
Ages
6 Years to 40 Years
Sex
All
01

Study summary

The aim of this study is to develop an intelligent, full-course case management model for patients with microtia, enabling them to receive continuous, individualized nursing and health management services across the stages from diagnosis and treatment to rehabilitation.

The study seeks to address the following questions:

What practical needs do patients with microtia and their families have throughout the treatment process? How can case management and an information-based platform be used to provide continuous, personalized health management for these patients? Does implementation of an intelligent case management model improve patient health education, follow-up management and care experience?

What will participants be asked to do? During microtia-related diagnosis and treatment,

Participants will:

Establish a personal health record documenting disease- and treatment-related information; Receive stage-specific, individualized health education and nursing guidance; Obtain treatment reminders, follow-up notifications and rehabilitation tasks via an information platform; Complete corresponding health management tasks under the guidance of healthcare professionals; Communicate online with healthcare providers through the platform and provide timely feedback on treatment and rehabilitation; Undergo scheduled follow-up and outcome assessments. Through these procedures, the research team will integrate patients' fragmented needs for diagnosis, treatment, nursing and rehabilitation at different stages, forming a continuous management process that spans the entire course of care.

Read the detailed description

This study comprises two phases. In phase I, a case-management platform for patients with microtia will be developed. Semi-structured interviews with patients, family members, plastic surgeons, anaesthesiologists, clinical nurses and social workers, together with a literature review and expert meetings, will be conducted to inform platform design. Phase II is the effectiveness evaluation. Patients admitted for ear reconstruction surgery at the Eye, Ear, Nose and Throat Hospital of Fudan University between January and June 2026 will be assigned to the control group and receive routine care. Patients admitted between July and December 2026 will be assigned to the intervention group and receive care supported by the microtia case-management platform. Recruitment for the intervention cohort will begin after completion of control cohort enrolment, with no overlap. No randomisation will be performed. Primary and secondary outcomes will be compared between the two cohorts.

02

Conditions studied

  • Congenital Microtia

Browse trials for

Keywords

  • Congenital microtia
  • whole-course care
  • case management
  • mobile health
  • intelligent nursing
03

In context

Congenital Microtia

33 studies on the registry are indexed under Congenital Microtia; 10 are open to participants now.

This study's planned enrollment of 188 is above the median of 34 across 23 interventional studies indexed under Congenital Microtia.

Browse Congenital Microtia studies →

Lead sponsor

Jing Xu is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 6-40 years
  • Meeting the diagnostic criteria for microtia as defined in Plastic Surgery of China, presenting typical microtia morphology and undergoing auricular reconstruction
  • Patients undergoing staged total ear reconstruction (including first-stage framework placement and ear elevation) or expander-based total ear reconstruction (expander implantation and semi-covered technique); temporoparietal fascia flap surgery; external auditory canal surgery

Exclusion criteria

Exclusion Criteria:

  • Abnormal coagulation or other laboratory findings
  • Absence of normal fascial coverage of the affected ear, or presence of eczema, infection or other local pathology on the affected side
  • Severe cognitive impairment or psychiatric disorders
  • Concomitant major organ dysfunction
  • Refusal by the patient or family to participate in the study
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
188 participants (estimated)

Study arms

  • No intervention
    Control group

    The control group will receive standard care according to current departmental practice, including routine perioperative nursing, conventional health education, discharge guidance and standard follow-up, without use of the intelligent case-management platform.

  • Experimental
    Intervention group

    In addition to standard care, the intervention group will use the microtia case-management platform.

    Other: Microtia case-management platform

Interventions

  • OtherMicrotia case-management platform

    An intelligent, whole-course case-management model will be implemented for patients with microtia. Continuous electronic health records will be established, and stage-specific individualized health education, rehabilitation guidance and follow-up tasks will be provided. The platform will enable health information updates, task check-ins, message-based communication and online follow-up.

06

What researchers measure

Primary outcomes

  1. Incidence of postoperative complications after ear reconstruction

    This study includes common complications after ear reconstruction, namely haematoma, infection, flap necrosis, framework exposure and pressure injury. The incidence of postoperative complications is calculated as: incidence = (number of patients with complications / total number of patients) × 100%.

    Time frame: Assessed 3 months postoperatively

Secondary outcomes

  1. Health education awareness rate

    A self-developed questionnaire on health education awareness will be used. The questionnaire covers eight domains: postoperative disease knowledge, diet, precautions for postoperative activity, postoperative medication, catheter- and pain-related education, postoperative wound observation and discharge health education. Each item has three response options (aware, partly aware, and unaware), with "partly aware" and "unaware" both classified as unaware. Health education awareness rates will be calculated for the control and intervention groups using the formula: health education awareness rate = (number of unaware items / total number of items) × 100%.

    Time frame: Assessed 1 day before discharge

  2. Patients' anxiety symptoms

    The Screen for Child Anxiety Related Emotional Disorders (SCARED) is a self-report instrument for children and adolescents that assesses anxiety disorders across five factors: somatic/panic, generalized anxiety, separation anxiety, social phobia and school phobia. It comprises 41 items, each rated on a three-point scale from 0 to 2 (0: not true; 1: somewhat true; 2: very true). Higher scores indicate more severe anxiety.

    Time frame: Assessed 1 month after discharge

  3. Caregivers' anxiety symptoms

    SAS is used to assess the subjective experience of anxiety and consists of 20 items, each scored on a four-point scale. Five items are positively worded (items 5, 9, 13, 17 and 19), and 15 items are negatively worded (all remaining items). Family members of patients are assessed using the SAS: scores \<50 indicate no anxiety, 50-59 mild anxiety, 60-69 moderate anxiety and \>69 severe anxiety. Higher scores denote greater anxiety severity. In this study, the SAS is used to evaluate anxiety in patients aged 16 years or older and their caregivers.

    Time frame: Assessed 1 month after discharge

  4. Patient follow-up rate

    The follow-up rates of patients in the control and intervention groups at 1 and 3 months after discharge were calculated as: patient follow-up rate = (number of patients who actually participated in follow-up / total number of patients scheduled for follow-up) × 100%.

    Time frame: Assessed at 1 and 3 months after discharge

  5. Quality of life of patients

    Quality of life was assessed using the Quality of Life Scale for Patients with Congenital Middle and External Ear Malformation. This scale evaluates three dimensions-physical functioning, psychological status and social relationships-with 18 items in total. Each item is scored on a five-point scale from 0 to 4; higher scores indicate poorer quality of life.

    Time frame: Assessed 1 month after discharge

  6. Patient satisfaction

    Evaluated using a self-designed satisfaction questionnaire comprising 15 items across five domains: consultation process and environment, quality of medical and nursing services, attitude of medical and nursing staff, health education and use of the information platform. Each item is rated on a three-point Likert scale (3 = satisfied, 2 = basically satisfied, 1 = dissatisfied), yielding a total score of 15-45. The sum of item scores represents overall satisfaction, with higher scores indicating greater patient satisfaction.

    Time frame: Assessed 1 month after discharge

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Perera S, Dabney BW. Case management service quality and patient-centered care. J Health Organ Manag. 2020 Jun 24;ahead-of-print(ahead-of-print). doi: 10.1108/JHOM-12-2019-0347. PubMed 32584524 ↗
  • Zhou Y, Li X, Zhang M, Lv G, Duan B, Tang Z. Effect of Multimedia Health Education on Psychological Burden, Quality of Life Ability, and Self-Efficacy of Congenital Microtia. Comput Math Methods Med. 2022 Aug 11;2022:1482865. doi: 10.1155/2022/1482865. eCollection 2022. PubMed 35991152 ↗
  • Kim HAJ, Namavarian A, Khan U, Levy BB, Ziai H, Talei B, Gantous AM. Reconstructive Techniques in Pediatric Congenital Microtia: A Systematic Review and Meta-analysis. Facial Plast Surg. 2025 Apr;41(2):204-211. doi: 10.1055/a-2247-5109. Epub 2024 Jan 17. PubMed 38232751 ↗
  • Torres I, Martinez JDC, Sanabria R, Gonzalez LV, Diaz-Baez D. Postoperative Safety and Satisfaction in Patients With Microtia. J Oral Maxillofac Surg. 2021 Feb;79(2):472.e1-472.e9. doi: 10.1016/j.joms.2020.09.004. Epub 2020 Sep 8. PubMed 33010219 ↗
  • Asirova GV, Wynands J, Almeida DL. Improvement of Quality of Life After Microtia Reconstruction Using a Modified Firmin Technique-Case Series of 130 Patients. Aesthetic Plast Surg. 2025 Jul;49(13):3528-3537. doi: 10.1007/s00266-025-04697-z. Epub 2025 Feb 7. PubMed 39920383 ↗
  • Hilewitz D, Olshinka A. Early Non-Surgical Treatment For Microtia Types 1 and 2. J Craniofac Surg. 2024 Jul-Aug 01;35(5):1509-1512. doi: 10.1097/SCS.0000000000010279. Epub 2024 May 14. PubMed 38743060 ↗
  • Patel KR, Benchetrit L, Ronner EA, Occhiogrosso J, Hadlock T, Shaye D, Quesnel AM, Cohen MS. Development of an interdisciplinary microtia-atresia care model: A single-center 20-year experience. Laryngoscope Investig Otolaryngol. 2022 Nov 16;7(6):2103-2111. doi: 10.1002/lio2.896. eCollection 2022 Dec. PubMed 36544952 ↗
  • Turhan Damar H, Ogce Aktas F. Anxiety, Depression, Stress, and Self-Esteem in Turkish Parents of Children with Microtia. Cleft Palate Craniofac J. 2024 Dec;61(12):1981-1990. doi: 10.1177/10556656231190046. Epub 2023 Jul 24. PubMed 37488938 ↗
  • Reinisch JF, van Hovell Tot Westerflier CVA, Gould DJ, Tahiri YT. Secondary Salvage of the Unsatisfactory Microtia Reconstruction. Plast Reconstr Surg. 2020 May;145(5):1252-1261. doi: 10.1097/PRS.0000000000006766. PubMed 32332549 ↗
  • Fan Y, Liu W, Fan X, Niu X, Chen X. Psychosocial status of patients with unilateral and bilateral microtia before auricular reconstruction surgery. Int J Pediatr Otorhinolaryngol. 2021 Dec;151:110928. doi: 10.1016/j.ijporl.2021.110928. Epub 2021 Sep 25. PubMed 34607045 ↗
  • Deng K, Dai L, Yi L, Deng C, Li X, Zhu J. Epidemiologic characteristics and time trend in the prevalence of anotia and microtia in China. Birth Defects Res A Clin Mol Teratol. 2016 Feb;106(2):88-94. doi: 10.1002/bdra.23462. Epub 2015 Dec 17. PubMed 26681129 ↗
  • Luquetti DV, Heike CL, Hing AV, Cunningham ML, Cox TC. Microtia: epidemiology and genetics. Am J Med Genet A. 2012 Jan;158A(1):124-39. doi: 10.1002/ajmg.a.34352. Epub 2011 Nov 21. PubMed 22106030 ↗
  • Li Q, Zhou X, Wang Y, Qian J, Zhang Q. Auricular reconstruction of congenital microtia by using the modified Nagata method: Personal 10-Year experience with 1350 cases. J Plast Reconstr Aesthet Surg. 2018 Oct;71(10):1462-1468. doi: 10.1016/j.bjps.2018.05.036. Epub 2018 Jun 19. PubMed 30097399 ↗
  • Behrens B, Swetlitz C, Pine DS, Pagliaccio D. The Screen for Child Anxiety Related Emotional Disorders (SCARED): Informant Discrepancy, Measurement Invariance, and Test-Retest Reliability. Child Psychiatry Hum Dev. 2019 Jun;50(3):473-482. doi: 10.1007/s10578-018-0854-0. PubMed 30460424 ↗
  • Dunstan DA, Scott N, Todd AK. Screening for anxiety and depression: reassessing the utility of the Zung scales. BMC Psychiatry. 2017 Sep 8;17(1):329. doi: 10.1186/s12888-017-1489-6. PubMed 28886698 ↗
  • Ren YY, Zhao SQ. [Development and evaluation of a quality of life scale specific to patients with congenital external and middle ear malformation]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2010 Aug;45(8):623-7. Chinese. PubMed 21055235 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared with external researchers due to patient privacy protection and institutional data policy. Aggregated study results will be reported in publications.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Dec 2026, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Sep 29, 2026
StartActual
Jul 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Aug 31, 2027
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07846345
Lead sponsor
Jing Xu
Responsible party
Jing Xu (Charge Nurse Practitioner, Eye & ENT Hospital of Fudan University) — Sponsor-investigator
First posted
Sep 29, 2026
Start date
Jul 1, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Sep 29, 2026

Study contacts

Jiaying Gao
Contact
1254091997@qq.com
+86 13795315458

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion